- Home
- PANW vs REGN Comparison
PANW vs REGN Comparison
Compare PANW & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANW
- REGN
- Stock Information
- Founded
- PANW 2005
- REGN 1988
- Country
- PANW United States
- REGN United States
- Employees
- PANW N/A
- REGN N/A
- Industry
- PANW Computer peripheral equipment
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- PANW Technology
- REGN Health Care
- Exchange
- PANW Nasdaq
- REGN Nasdaq
- Market Cap
- PANW 124.9B
- REGN 59.5B
- IPO Year
- PANW 2012
- REGN 1991
- Fundamental
- Price
- PANW $201.34
- REGN $575.06
- Analyst Decision
- PANW Buy
- REGN Buy
- Analyst Count
- PANW 44
- REGN 23
- Target Price
- PANW $212.99
- REGN $794.83
- AVG Volume (30 Days)
- PANW 7.3M
- REGN 947.1K
- Earning Date
- PANW 08-18-2025
- REGN 10-30-2025
- Dividend Yield
- PANW N/A
- REGN 0.61%
- EPS Growth
- PANW N/A
- REGN 5.03
- EPS
- PANW 1.60
- REGN 39.67
- Revenue
- PANW $9,221,500,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- PANW $16.28
- REGN N/A
- Revenue Next Year
- PANW $13.43
- REGN $4.86
- P/E Ratio
- PANW $125.88
- REGN $14.50
- Revenue Growth
- PANW 14.87
- REGN 5.38
- 52 Week Low
- PANW $144.15
- REGN $476.49
- 52 Week High
- PANW $210.39
- REGN $1,165.85
- Technical
- Relative Strength Index (RSI)
- PANW 68.74
- REGN 53.36
- Support Level
- PANW $196.16
- REGN $558.54
- Resistance Level
- PANW $202.11
- REGN $570.76
- Average True Range (ATR)
- PANW 4.13
- REGN 13.98
- MACD
- PANW 1.21
- REGN -1.01
- Stochastic Oscillator
- PANW 92.35
- REGN 50.33
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).